Customer Contact Center:
1-888-PLMZYME (756-9963)

Indication

Pulmozyme® (dornase alfa) is indicated for daily administration along with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function.

In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.

Important Safety Information

Pulmozyme should not be used in patients who are allergic to any of its ingredients.

Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

For further information, please see the Pulmozyme full Prescribing Information.

Pediatric Use

The safety and effectiveness of Pulmozyme have been established in patients 5 years of age and older. While clinical trial data are limited in patients younger than 5 years of age, the use of PULMOZYME should be considered for pediatric CF patients who may experience potential benefit in lung function or who may be at risk of respiratory tract infection.

The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to <5 years (younger group) and 33 aged 5 years to <10 years (older group). The PARI BABY™ reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. Overall, the kind of side effects observed in children was similar to those seen in larger trials in older patients.

Customer Contact Center

1-888-PLMZYME (756-9963)

Pulmozyme Access Solutions®

The CF Living community

Resource Center

CFLiving.com

CF Living is an online community for CF patients and caregivers to get information and learn about others living with this disease.

CF Living is a free program featuring helpful information for patients and caregivers. After you register, you’ll receive regular, personalized emails with relevant information about CF according to the age of the patient and you’ll also receive updates about exciting additions to cfliving.com.

Register Now at www.cfliving.com

The program includes topics surrounding:

  • Tips for managing treatment
  • Balancing CF with school or work
  • Recipes and nutritional information
  • Links to additional resources for support

When you join, you will also have the opportunity to receive one of the following:

  • A Pulmozyme Patient Kit with resources, information, and tips
  • A printed copy of an Illustrated Story about a student who faces challenges of CF and how he takes control
  • A USB Webkey that provides access to a webcast that discusses how CF can progress when symptoms are not visible

We look forward to you becoming part of the community!

Register Now at www.cfliving.com

Please see our Privacy Policy.